One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Covid-19 and the Safety Net — Moving from Straining to Sustaining
Janine Knudsen, M.D., and Dave A. Chokshi, M.D.
doi : 10.1056/NEJMp2114010
N Engl J Med 2021; 385:2209-2211
Inequitable Access to Hospital Care — Protecting Disadvantaged Populations during Public Health Emergencies
Douglas B. White, M.D., Lisa Villarroel, M.D., M.P.H., and John L. Hick, M.D.
doi : 10.1056/NEJMp2114767
N Engl J Med 2021; 385:2211-2214
Emperor of the Empire
Margaret S. Bravo, R.N.C.
doi : 10.1056/NEJMp2111460
N Engl J Med 2021; 385:2215-2217
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Mark G. Lebwohl, M.D., Linda Stein Gold, M.D., Bruce Strober, M.D., Ph.D, Kim A. Papp, M.D., Ph.D., April W. Armstrong, M.D., Jerry Bagel, M.D., Leon Kircik, M.D., Benjamin Ehst, M.D., Ph.D., H. Chih-ho Hong, M.D., Jennifer Soung, M.D., Jeff Fromowitz, M.D., Scott Guenthner, M.D., Stephen C. Piscitelli, Pharm.D., David S. Rubenstein, M.D., Ph.D., Philip M. Brown, M.D., J.D., Anna M. Tallman, Pharm.D., and Robert Bissonnette, M.D.
doi : 10.1056/NEJMoa2103629
N Engl J Med 2021; 385:2219-2229
Tapinarof cream is a topical aryl hydrocarbon receptor–modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin.
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Leonard B. Bacharier, M.D., Jorge F. Maspero, M.D., Constance H. Katelaris, M.D., Alessandro G. Fiocchi, M.D., Remi Gagnon, M.D., Ines de Mir, M.D., Neal Jain, M.D., Lawrence D. Sher, M.D., Xuezhou Mao, Ph.D., Dongfang Liu, M.S., Yi Zhang, Ph.D., M.P.H., Asif H. Khan, M.B., B.S., M.P.H., Upender Kapoor, M.D., Faisal A. Khokhar, M.D., Paul J. Rowe, M.D., Yamo Deniz, M.D., Marcella Ruddy, M.D., Elizabeth Laws, Ph.D., Naimish Patel, M.D., David M. Weinreich, M.D., George D. Yancopoulos, M.D., Ph.D., Nikhil Amin, M.D., Leda P. Mannent, M.D., David J. Lederer, M.D., and Megan Hardin, M.D., M.P.H. for the Liberty Asthma VOYAGE Investigators*
doi : 10.1056/NEJMoa2106567
N Engl J Med 2021; 385:2230-2240
Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well as with other type 2 inflammatory diseases.
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Kashif Ali, M.D., Gary Berman, M.D., Honghong Zhou, Ph.D., Weiping Deng, Ph.D., Veronica Faughnan, B.S., Maria Coronado-Voges, M.S., Baoyu Ding, M.S., Jacqueline Dooley, B.A., Bethany Girard, Ph.D., William Hillebrand, M.S., Rolando Pajon, Ph.D., Jacqueline M. Miller, M.D., Brett Leav, M.D., and Roderick McPhee, M.D., Ph.D.
doi : 10.1056/NEJMoa2109522
N Engl J Med 2021; 385:2241-2251
The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Bertram Pitt, M.D., Gerasimos Filippatos, M.D., Rajiv Agarwal, M.D., Stefan D. Anker, M.D., Ph.D., George L. Bakris, M.D., Peter Rossing, M.D., Amer Joseph, M.B., B.S., Peter Kolkhof, Ph.D., Christina Nowack, M.D., Patrick Schloemer, Ph.D., and Luis M. Ruilope, M.D. for the FIGARO-DKD Investigators*
doi : 10.1056/NEJMoa2110956
N Engl J Med 2021; 385:2252-2263
Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear.
Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
Maximilian Kueckelhaus, M.D., Tobias Rothoeft, M.D., Laura De Rosa, Ph.D., Burcu Yeni, B.Sc., Tobias Ohmann, Ph.D., Christoph Maier, M.D., Lynn Eitner, M.D., Dieter Metze, M.D., Lorena Losi, M.D., Ph.D., Alessia Secone Seconetti, Ph.D., Michele De Luca, M.D., and Tobias Hirsch, M.D.
doi : 10.1056/NEJMoa2108544
N Engl J Med 2021; 385:2264-2270
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Hiam Chemaitelly, M.Sc., Patrick Tang, M.D., Ph.D., Mohammad R. Hasan, Ph.D., Sawsan AlMukdad, M.Sc., Hadi M. Yassine, Ph.D., Fatiha M. Benslimane, Ph.D., Hebah A. Al Khatib, Ph.D., Peter Coyle, M.D., Houssein H. Ayoub, Ph.D., Zaina Al Kanaani, Ph.D., Einas Al Kuwari, M.D., Andrew Jeremijenko, M.D., Anvar H. Kaleeckal, M.Sc., Ali N. Latif, M.D., Riyazuddin M. Shaik, M.Sc., Hanan F. Abdul Rahim, Ph.D., Gheyath K. Nasrallah, Ph.D., Mohamed G. Al Kuwari, M.D., Hamad E. Al Romaihi, M.D., Adeel A. Butt, M.B., B.S., Mohamed H. Al-Thani, M.D., Abdullatif Al Khal, M.D., Roberto Bertollini, M.D., M.P.H., and Laith J. Abu-Raddad, Ph.D.
doi : 10.1056/NEJMoa2114114
N Engl J Med 2021; 385:e83
Waning of vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or coronavirus disease 2019 (Covid-19) is a concern. The persistence of BNT162b2 (Pfizer–BioNTech) vaccine effectiveness against infection and disease in Qatar, where the B.1.351 (or beta) and B.1.617.2 (or delta) variants have dominated incidence and polymerase-chain-reaction testing is done on a mass scale, is unclear.
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Einav G. Levin, M.D., Yaniv Lustig, Ph.D., Carmit Cohen, Ph.D., Ronen Fluss, M.Sc., Victoria Indenbaum, Ph.D., Sharon Amit, M.D., Ram Doolman, Ph.D., Keren Asraf, Ph.D., Ella Mendelson, Ph.D., Arnona Ziv, M.Sc., Carmit Rubin, M.Sc., Laurence Freedman, Ph.D., Yitshak Kreiss, M.D., and Gili Regev-Yochay, M.D.
doi : 10.1056/NEJMoa2114583
N Engl J Med 2021; 385:e84
Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel. Whether the increasing incidence of infection is due to waning immunity after the receipt of two doses of the BNT162b2 vaccine is unclear.
Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg, Ph.D., Micha Mandel, Ph.D., Yinon M. Bar-On, M.Sc., Omri Bodenheimer, M.Sc., Laurence Freedman, Ph.D., Eric J. Haas, M.D., Ron Milo, Ph.D., Sharon Alroy-Preis, M.D., Nachman Ash, M.D., and Amit Huppert, Ph.D.
doi : 10.1056/NEJMoa2114228
N Engl J Med 2021; 385:e85
In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a resurgent Covid-19 outbreak began in mid-June 2021. Possible reasons for the resurgence were reduced vaccine effectiveness against the delta (B.1.617.2) variant and waning immunity. The extent of waning immunity of the vaccine against the delta variant in Israel is unclear.
Latent Tuberculosis Infection
Maunank Shah, M.D., Ph.D., and Susan E. Dorman, M.D.
doi : 10.1056/NEJMcp2108501
N Engl J Med 2021; 385:2271-2280
Transverse Nasal Creases
Bin Zhang, M.D., and Lin Ma, M.D.
doi : 10.1056/NEJMicm2111716
N Engl J Med 2021; 385:2281
Congenital Langerhans-Cell Histiocytosis
Anil Kallesh, M.B., B.S., M.D., D.M., and Vikram S. Kumar, M.B., B.S., M.D.
doi : 10.1056/NEJMicm2112460
N Engl J Med 2021; 385:e86
Case 37-2021: A 60-Year-Old Man with Fevers, Fatigue, Arthralgias, a Mouth Ulcer, and a Rash
Zachary S. Wallace, M.D., Karen Rodriguez, M.D., Jonathan Dau, M.D., Donald B. Bloch, M.D., and Samantha N. Champion, M.D.
doi : 10.1056/NEJMcpc2107353
N Engl J Med 2021; 385:2282-2293
AhR Modulating Agent for the Topical Therapy of Plaque Psoriasis
Thomas Bieber, M.D., Ph.D., M.D.R.A.
doi : 10.1056/NEJMe2116301
N Engl J Med 2021; 385:2295-2296
Need for Racial and Ethnic Diversity in Asthma Precision Medicine
Esteban González Burchard, M.D., M.P.H., and Luisa N. Borrell, D.D.S., Ph.D.
doi : 10.1056/NEJMe2114944
N Engl J Med 2021; 385:2297-2298
Audio Interview: Waning Immunity against SARS-CoV-2
Eric J. Rubin, M.D., Ph.D., Lindsey R. Baden, M.D., and Stephen Morrissey, Ph.D.
doi : 10.1056/NEJMe2119211
N Engl J Med 2021; 385:e99
Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex
doi : 10.1056/NEJMc2115045
N Engl J Med 2021; 385:2299
Effectiveness of the mRNA-1273 Vaccine during a SARS-CoV-2 Delta Outbreak in a Prison
doi : 10.1056/NEJMc2114089
N Engl J Med 2021; 385:2300-2301
Getting Proximate — Flipping the Mentorship Paradigm to Promote Health Equity
Aditi Vasan, M.D., Ashlee Harris, C.H.W., Shreya Kangovi, M.D., and Kevin B. Mahoney, D.B.A.
doi : 10.1056/NEJMpv2116137
N Engl J Med 2021; 385:e89
